- |||||||||| Clinical, Journal: LncRNA and mRNA expression associated with myasthenia gravis in patients with thymoma. (Pubmed Central) - Feb 3, 2022
Comorbidities in older patients with myasthenia are very common, increase with age, and do not differ between early- and late-onset disease. MG-positive thymoma is associated with overactive biological processes and molecular functions, especially dephosphorylation and hydrolysis, which may affect thymocyte survival during selection in the thymus.
- |||||||||| Review, Journal: Management of ptosis (Pubmed Central) - Feb 3, 2022
Except for "urgent ptosis", requiring multidisciplinary medical treatment, surgery is the mainstay of treatment. The surgical technique is based on the etiology of the ptosis, the strength of the levator muscle and the phenylephrine test.
- |||||||||| abiraterone acetate / Generic mfg., nifedipine immediate release / Generic mfg.
Review, Journal: The Expanding Role of Pyridine and Dihydropyridine Scaffolds in Drug Design. (Pubmed Central) - Feb 2, 2022
This review examines the prospects of highly potent bioactive molecules to emphasize the advantages of using pyridine and dihydropyridine in drug design. We cover the most recent developments from 2010 to date, highlighting the ever-expanding role of both scaffolds in the field of medicinal chemistry and drug development.
- |||||||||| Review, Journal: Advances and ongoing research in the treatment of autoimmune neuromuscular junction disorders. (Pubmed Central) - Feb 2, 2022
These new therapies extend the possibilities for targeted immunotherapies and promise exciting new options with a relatively rapid mode of action. Challenges in their use might occur, with barriers due to an increase in cost of care and additional considerations in the choice of drugs, and potential consequences of infection and vaccination due to the COVID-19 pandemic.
- |||||||||| Journal: A New Option Is Approved for Patients With Myasthenia Gravis. (Pubmed Central) - Feb 2, 2022
Challenges in their use might occur, with barriers due to an increase in cost of care and additional considerations in the choice of drugs, and potential consequences of infection and vaccination due to the COVID-19 pandemic. No abstract available
- |||||||||| Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Journal: Rituximab in Myasthenia Gravis - Where do we stand? (Pubmed Central) - Feb 1, 2022
With availability of cheaper biosimilars and subcutaneous formulations of Rituximab, its off label usage in MG is likely to increase. Data from larger controlled studies will be needed for regulatory approval of Rituximab in MG.
- |||||||||| Review, Journal: Myasthenia Gravis and Myeloproliferative Neoplasms - Mere Association or Paraneoplastic Neurologic Syndrome: A Mini-Review. (Pubmed Central) - Feb 1, 2022
Considering that 10 out of the 13 patients in our cohort had positive auto-antibodies though only 4 of them had thymic hyperplasia, we hypothesize that bone marrow proliferation was responsible for the production of autoantibodies in these patients.As the clonal cell population cannot be eliminated entirely in the bone marrow even after treatment with tyrosine kinase inhibitors (TKI) in Ph +ve MPNs and JAK2 inhibitors in Ph -ve MPNS, MG can occur even in patients who are treated with these agents. A high index of suspicion is needed to diagnose it early, and treatment should be initiated immediately with steroids and anticholinergic agents.
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
The triple M threat of check-point inhibitorsan emerging overlap syndrome. () - Jan 30, 2022 - Abstract #BSR2022BSR_317;
With ICI reshaping the prognosis of several cancers and pembrolizumab gaining recent further approvals, we will increasingly encounter this therapeutic challenge. Therefore, raising awareness of this overlap syndrome amongst rheumatologists is even more critical to allow for prompt recognition and treatment with immunosuppression.
- |||||||||| Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Journal, IO biomarker: Memory B Cells Predict Relapse in Rituximab-Treated Myasthenia Gravis. (Pubmed Central) - Jan 29, 2022
The percentage of memory B cells in whole blood cells can accurately predict clinical relapse in myasthenia gravis patients treated with rituximab. This monitoring allows physicians to tailor rituximab administration and to decrease the number of infusions over time.
- |||||||||| plasma exchange (PLEX) / Mayo Clinic, Terumo Corp
Review, Journal: The Role of Plasma Exchange in the Treatment of Refractory Autoimmune Neurological Diseases: a Narrative Review. (Pubmed Central) - Jan 29, 2022
Success rates can also differ within 'one' disease: e.g. response rates to PLEX are considerably higher in refractory relapsing remitting MS compared to primary or secondary progressive MS. When sufficient efforts are made to correctly pinpoint the diagnosis along with the type and subtype of refractory autoimmune disease, PLEX and other immunotherapies can play a valuable role in the patient management.
- |||||||||| Journal: Neuromuscular hyperexcitability syndromes. (Pubmed Central) - Jan 29, 2022
This review provides an update on recent clinical, immunological and genetic developments in neuromuscular hyperexcitability syndromes. We also provide a guide for the clinician for diagnosing and managing these disorders in clinical practice, with a special focus on the main differential diagnoses.
- |||||||||| Review, Journal, Checkpoint inhibition: CNS and PNS manifestation in immune checkpoint inhibitors: A systematic review. (Pubmed Central) - Jan 29, 2022
This systematic literature review describes the largest collection of neurological irAEs to date including both CNS and PNS manifestations of ICIs. The information described herein can be used to better inform monitoring and treatment of patients undergoing treatment with ICIs.
- |||||||||| Clinical, Journal: Clinical, Methodological, and Practical Considerations for Algorithmic Testing in Autoimmune Serology. (Pubmed Central) - Jan 29, 2022
Serology reflex testing algorithms for the evaluation of autoimmune diseases can support clinical diagnosis and laboratory resource use but may be challenging to implement and are often applied variably across institutions. Assessments of evidence-driven guidelines, clinical impact, and impact on laboratory workflow are essential to this task.
- |||||||||| Clinical, Journal: Disease severity and response to treatment in Iranian patients with myasthenia gravis. (Pubmed Central) - Jan 28, 2022
The overall outcome was favorable in the majority of patients, despite differences in the disease course and severity. In contrary to the previous reports, anti-MuSK positive patients in our series did not need a more vigorous treatment regimen comparing other serologic subtypes of MG.
- |||||||||| Journal: First characterization of congenital myasthenic syndrome type 5 in North Africa. (Pubmed Central) - Jan 28, 2022
COLQ mutations are probably underdiagnosed in these North African populations, this is an issue as CMS-5 may be treated with ephedrine, and albuterol. Indeed, patients can seriously benefit and even recover after the treatment that should be planned according to genetic tests and clinical findings.
- |||||||||| Biomarker, Journal: Competitive endogenous RNA network and pathway-based analysis of LncRNA single-nucleotide polymorphism in myasthenia gravis. (Pubmed Central) - Jan 28, 2022
Finally, functional analyses demonstrated lncRNA-SNPs mediated ceRNA regulation pairs associated with MG participated in the MAPK signaling pathway. In summary, we constructed MG-specific lncRNA-SNPs mediated ceRNA regulatory networks based on pathway in the present study, which was helpful to elucidate the roles of lncRNA-SNPs in the pathogenesis of MG and provide novel insights into mechanism of lncRNA-SNPs as potential genetic risk biomarkers of MG.
- |||||||||| Zilbrysq (zilucoplan) / UCB
Trial completion: RAISE: Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis (clinicaltrials.gov) - Jan 28, 2022
P3, N=174, Completed,
In summary, we constructed MG-specific lncRNA-SNPs mediated ceRNA regulatory networks based on pathway in the present study, which was helpful to elucidate the roles of lncRNA-SNPs in the pathogenesis of MG and provide novel insights into mechanism of lncRNA-SNPs as potential genetic risk biomarkers of MG. Active, not recruiting --> Completed
- |||||||||| Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J
UPFRONT IMMUNOMODULATORY TREATMENT OF IMMUNE CHECKPOINT INHIBITOR MYOCARDITIS (Special Topics Moderated Poster Theater 5_Hall C) - Jan 28, 2022 - Abstract #ACC2022ACC_7070;
The use of a UIM protocol in addition to steroids shows promise of decreased MACE without an increased risk of sepsis. Given the small number of patients treated with UIM, further studies are needed to better define the efficacy of the UIM protocol.
- |||||||||| Covaxin (BBV152 COVID Vaccine) / Bharat Biotech, Indian Council of Medical Research, Ocugen
A CASE OF MYOCARDITIS AND MYOSITIS FOLLOWING COVID19 VACCINE (eAbstract site) - Jan 28, 2022 - Abstract #ACC2022ACC_6730;
Myocarditis in our patient may be related to either COVID infection or vaccine. Etiology of his acute on chronic myopathy from mitochondrial dysfunction is curious since COVID is also known to impact mitochondrial function.
- |||||||||| MYASTHENIA GRAVIS ASSOCIATED MYOCARDITIS SUCCESSFULLY TREATED WITH EMPIRIC IMMUNOSUPPRESSION (Poster Hall_Hall C) - Jan 28, 2022 - Abstract #ACC2022ACC_6291;
Myocarditis is a rare complication of MG but is more common with older age at diagnosis, thymoma, and anti-striated muscle antibodies which appear to be particularly important in the pathogenesis of this condition. Empiric early multimodal immunosuppression regimens including high dose steroids and azathioprine may be considered in this setting however randomized data is needed to determine the true impact of this strategy.
- |||||||||| Procoralan (ivabradine) / Amgen, Servier, Ono Pharma
MYASTHENIA GRAVIS AND TAKOTSUBO SYNDROME (eAbstract site) - Jan 28, 2022 - Abstract #ACC2022ACC_2921;
In patients with MG, Takotsubo syndrome has to be seen as a plausible and probable cause of chest pain, even if the patient is at rest and with no emotional distress, as in the classical presentation. The treatment strategy also has to be individualized, with ivabradine being a good alternative for betablockers.
- |||||||||| Raised ✋🏻: curiously after frequent TIAs,“ischemic event”,“I think it is subarachnoid hemorrhage”,“maybe it is Chiari”, “maybe hemiplegic migraine”, “PRES on CT scan, don’t know why”, IVIG, given for Myasthenia Gravis stopped them, but those episodes are not features of MG 1/2 (Twitter) - Jan 27, 2022
- |||||||||| Journal: High mobility group box 1 is involved in the pathogenesis of passive transfer myasthenia gravis model. (Pubmed Central) - Jan 27, 2022
As a result, serum HMGB1 levels tended to be higher and the quantitative score of muscle pathology showed greater HMGB1 deposition (P = 0.02) along with sparser AChR staining and more severe inflammation in the passive transfer MG rats (n = 6) than those in control rats (n = 6). These findings indicate that HMGB1 is an important mediator and biomarker for inflammation in the pathogenesis of MG and can be a therapeutic target in MG.
- |||||||||| Journal: Emerging drugs for the treatment of Myasthenia Gravis. (Pubmed Central) - Jan 27, 2022
Despite several promising novel agents, existing data as to the timing of initiation and duration of treatment, long term safety profile and utility in certain patient subsets are limited and require further research. Despite these considerations, the future of MG treatment is transitioning from broad-spectrum IST towards precise, target-driven and personalised immunotherapy.
- |||||||||| Tai'ai (telitacicept) / Rongchang Pharma
Review, Journal: Telitacicept: First Approval. (Pubmed Central) - Jan 27, 2022
Clinical studies of telitacicept in several other indications, including IgA nephropathy, MS, myasthenia gravis, neuromyelitis optica spectrum disorders, RA and Sjögren's syndrome are underway in China. This article summarizes the milestones in the development of telitacicept leading to this first approval for SLE.
|
